TP53 and B-cell chronic lymphocytic leukemia: It is important to obtain both these tests since ~3–5% of patients will harbor a deleterious TP53 mutation on DNA sequencing in the absence of del17p13 on CLL FISH, and multiple studies have shown these patients have equally poor outcomes [23–27].